Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonor Vasconcelos

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Cancer Treatment Reviews|May 22, 2026
Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposalAldo Caltavituro, Roberto Buonaiuto, Alessandra Longobardi, et al.
Breast Cancer Research and Treatment|July 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN studyDiogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, et al.
Cancer|May 16, 2024
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort studyFrancesco Schettini, Eva Blondeaux, Chiara Molinelli, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Cancer Treatment Reviews|May 22, 2026
Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposalAldo Caltavituro, Roberto Buonaiuto, Alessandra Longobardi, et al.
Breast Cancer Research and Treatment|July 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN studyDiogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, et al.
Cancer|May 16, 2024
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort studyFrancesco Schettini, Eva Blondeaux, Chiara Molinelli, et al.
Pageof 4